Vistagen Reports First Patient Dosing in P-I Study of PH10 to Treat Major Depressive Disorder
Shots:
- The first cohort has been dosed in P-I study evaluating the safety and tolerability of PH10 in patients (n=12) with MDD in the US. The study completion is expected by Q1’23 with top-line results before the H1’23
- The study is conducted to determine the safety profile equivalent to three previous clinical studies in Mexico incl. a published P-IIa study, as well as to execute development plans for a P-IIb study as a stand-alone treatment for MDD
- PH10, a pherine nasal spray with potential rapid-onset MOA. It binds to receptors of chemosensory neurons in the nasal passages and increases the activity of the limbic-hypothalamic sympathetic nervous system and thus increasing the release of catecholamines
Ref: Businesswire | Image: Vistagen
Related News:- VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD)
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
